Cognition Therapeutics Inc.
CGTX Nasdaq
SEC CIK 1455365
Follow Cognition Therapeutics
Weekly email: filings, results, news
Net income
−$3.9M
+41.6% vs same quarter last year
EPS, diluted
−$0.04
+63.6% vs same quarter last year
Operating cash flow
−$3.1M
+45.7% vs same quarter last year
Operating income
−$7.7M
+44.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$23.5M |
| FY24 | −$34M |
| FY23 | −$25.8M |
| FY22 | −$21.4M |
| FY21 | −$11.7M |
| FY20 | −$7.8M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$28.5M |
| FY23 | −$16.2M |
| FY22 | −$18.7M |
| FY21 | −$3.7M |
| FY20 | −$3.4M |
| FY19 | - |
News
No stories filed under Cognition Therapeutics yet - coverage appears here as the news feed clusters it.